Skip to main content

Table 5 Adverse events in 27 patients with unresectable refractory RRC and 9 patients with unresectable refractory CRC liver metastases submitted for Hypoxic Pelvic Perfusion (HPP)/targeted therapy or Hepatic Artery Infusion/targeted therapy based on in vitro CTC chemosensitivity and gene expressions analyses

From: Circulating tumour cell gene expression and chemosensitivity analyses: predictive accuracy for response to multidisciplinary treatment of patients with unresectable refractory recurrent rectal cancer or unresectable refractory colorectal cancer liver metastases

Adverse events

 

HPP/target-therapy, N = 27

HAI/target therapy, N = 9

Total, N = 36

 

Grade

N (%)

N (%)

N (%)

Bone marrow hypocellurarity

−1/2

3 (11)

1 (11)

4 (11)

−3/4

1 (4)

0

1 (3)

Nausea/vomiting

−1/2

3 (11)

1 (11)

4 (11)

−3/4

0

1 (11)

1 (3)

Diarrhea

−1/2

0

1 (11)

1 (3)

−3/4

0

0

0

Alopecia

−1/2

2 (7)

1 (11)

3 (8)

−3/4

0

0

0

Fatigue

−1/2

2 (7)

1 (11)

3 (8)

−3/4

0

0

0

Neuropaty

−1/2

2 (7)

1 (11)

3 (8)

−3/4

0

0

0

Hand Foot Syndrome

−1/2

0

1 (11)

1 (3)

−3/4

0

0

0

Rash

−1/2

0

2 (22)

2 (5.5)

−3/4

0

0

0

Non-infectious fever

−1/2

0

4 (44)

4 (11)

−3/4

0

0

0

Perineal skin toxicity

−1/2

6 (22)

0

6 (16.6)

−3/4

5 (18)

0

5 (14)

AST and ALT increased

−1/2

0

1 (11)

1 (3)

−3/4

0

0

0

Persistent leakage of fluid from the inguinal incision

−1/2

3 (11)

0

3 (8)

−3/4

1 (4)

0

1 (3)

Inguinal hematoma

-1/2

1 (4)

1 (11)

2 (5.5)

-3/4

0

0

0

  1. AST Aspartate transaminase, ALT Alanine transaminase